IGM Biosciences (NASDAQ:IGMS) just reported results for the first quarter of 2024.
- IGM Biosciences reported earnings per share of -83 cents. This met the analyst estimate for EPS of -83 cents.
- The company reported revenue of $497,000.
- This was 34.61% worse than the analyst estimate for revenue of $760,000.